Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing
Clinical Responses Observed in 67% of the Patients
and Clinical Remission Observed in 28% of the Patients
89% of the Patients Experienced a Reduction in Mayo Score, and 61% of the Patients
Experienced a Reduction in Endoscopic Sub Score
No Systemic Absorption Observed
CARMIEL, Israel, June 05, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today t...